Venture capital fund · 1 deal
Parkville, VIC
Every published round SYNthesis BioVentures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Skin2Neuron | Unnamed stage | 9 Apr 2024 | $4m | Participant | SmartCompany, Synthesis BioVentures |
Companies SYNthesis BioVentures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Skin2Neuron | Develops cell therapy to reverse Alzheimer's disease by restoring neurons | 9 Apr 2024 | 1 | 0 |
Investors that coverage says has money in a fund SYNthesis BioVentures runs. This is a stake in the fund, not in any company the fund has backed.
| Investor | Fund | Sources |
|---|---|---|
| Breakthrough Victoria | SYNthesis BioVentures Fund I | @AuManufacturing, Startup Daily, Breakthrough Victoria |
Companies SYNthesis BioVentures has backed that another company then bought. An exit for the holding, not a deal SYNthesis BioVentures did.
| Name | Role | Sources |
|---|---|---|
| Amir Zalcenstein | Managing Director | Synthesis BioVentures (21 Oct 2024), Synthesis BioVentures (9 Apr 2024) |
| Amir Zalcenstein | Co-managing Director | Synthesis BioVentures |
| Prof Andrew Wilks | Founder | Synthesis BioVentures |
| Prof Andrew Wilks | Founder | Startup Daily, Breakthrough Victoria (25 Oct 2025), Breakthrough Victoria (25 Oct 2025), Forbes Australia, Synthesis BioVentures |
Stories naming SYNthesis BioVentures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of manufacturing news: Archer Materials' biochip results with IMEC, Resmed's CPAP mask launch, Boeing's RAAF P-8A upgrades, Breakthrough Victoria's $75m across venture funds, an Avalon Airport freight facility, and Sleeptite's FlexiSense.
Victoria's Breakthrough Victoria has committed $75m to five specialist VC funds covering climate tech, life sciences, female founders and healthcare, each pledging a quarter of its capital to local startups.
Breakthrough Victoria is putting $75 million into five venture capital funds, including Virescent, SYNthesis BioVentures, Scale and Galileo, each of which has pledged a quarter of its capital to Victorian startups.
Breakthrough Victoria makes cornerstone investments totalling $75 million into five venture capital funds spanning climate-tech, biotech, diversity-focused and health sciences investing.
Synthesis BioVentures' fourth newsletter covers its backing of Qubigen; the captured page holds only a title and date, with no further detail.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
Sydney biotech Skin2Neuron raised $4 million from SYNthesis BioVentures to develop a hair-follicle cell therapy for Alzheimer's, while the investor reached the first $20 million close of its $75 million bioscience fund.
Also SmartCompany
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
The venture firm's newsletter records a A$2.25m SAFE investment in Aculeus Therapeutics, its fund's second deal, and outlines the immunology-oncology pipeline and long-standing individual backers behind the biotech.
Debut quarterly letter from SYNthesis BioVentures reporting A$18 million committed to its fund, an A$3.8 million stake in Catalyst Therapeutics' A$11.7 million seed round, and two senior appointments from the SYNthesis Group.